GRI Bio filings document a clinical-stage biotechnology issuer developing Natural Killer T cell modulators and the public-company events tied to that business. The filings include 8-K disclosures covering GRI-0621 clinical trial updates in idiopathic pulmonary fibrosis, financial-result releases and press-release exhibits furnished under results of operations and other-events items.
The filing record also details capital structure and governance matters, including at-the-market common stock offering agreements and prospectus supplements, legal opinions for share issuance, certificate amendments for a reverse stock split, Nasdaq Capital Market compliance notices, special meeting voting results and adjustments affecting common stock, warrants, convertible securities and equity incentive plans.
GRI Bio, Inc. reported first quarter 2026 results and highlighted new Phase 2a data for its IPF drug candidate GRI-0621. Cash and cash equivalents were approximately $11.0 million as of March 31, 2026, up from about $8.2 million at year-end 2025, which the company expects will fund operations into the second quarter of 2027.
In the 35-patient Phase 2a IPF trial, GRI-0621 added to standard of care showed zero cough versus 25% on placebo, a 76% reduction in dyspnea (4% vs. 17%), no weight loss versus 17% on placebo, and a 61% reduction in diarrhea (13% vs. 33%), with no serious adverse events in the active arm. Exploratory data showed a +99 mL FVC improvement overall and +139 mL in patients on background antifibrotics.
Research and development expenses fell to about $0.4 million from $1.6 million a year earlier as the Phase 2a trial concluded, while general and administrative expenses were approximately $1.6 million versus $1.4 million. Net loss narrowed to roughly $2.0 million from $3.0 million, and the company raised about $6.8 million in gross proceeds through its at-the-market facility.
GRI Bio, Inc. files an Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership. The filing states that, as of March 31, 2026, the Reporting Persons are each deemed to beneficially own 90,475 shares of common stock issuable upon exercise of a warrant held by Intracoastal, representing 5.9% of the company on the stated basis. The filing cites 1,445,029 shares outstanding as of January 29, 2026 used to calculate the percentage and discloses two additional warrants each for 3,472 shares that contain 4.99% blocker provisions. The filing is signed by Mitchell P. Kopin and Daniel B. Asher.
GRI Bio, Inc. reported a Q1 2026 net loss of $1.998M, narrowing from $3.046M a year earlier, as research and development spending fell to $0.361M from $1.64M after completing a Phase 2a trial of lead drug GRI-0621. General and administrative expenses rose to $1.642M, reflecting higher public company costs.
The company ended March 31, 2026 with $11.048M in cash and cash equivalents, helped by $6.8M of gross proceeds from an at-the-market stock program during the quarter. Management believes this cash funds operations into the second quarter of 2027 but warns it is insufficient to complete a Phase 2b trial of GRI-0621 without substantial additional capital. The filing states there is “substantial doubt” about GRI Bio’s ability to continue as a going concern absent new financing.
GRI Bio, Inc. shareholders Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher filed an amended Schedule 13G reporting their beneficial ownership of the company’s common stock. The filing focuses on their combined position and the structure of that holding.
As of the close of business on December 31, 2025, the reporting persons may have been deemed to beneficially own 1,097,858 shares of common stock, or 9.99% of the class. This includes 229,347 shares held by Intracoastal and 868,511 shares issuable upon exercise of one warrant. The ownership percentage is based on 10,121,060 shares outstanding as of December 19, 2025 plus the warrant shares counted for this calculation.
The filing explains that additional shares are potentially issuable under several warrants but are currently blocked from exercise by provisions that cap beneficial ownership at 9.99% for one warrant and 4.99% for three others. The investors certify that the securities were not acquired for the purpose of changing or influencing control of GRI Bio.
GRO Bio, Inc. received an amended Schedule 13G from Lincoln Alternative Strategies LLC reporting that it now beneficially owns 0 shares of GRO Bio common stock, representing 0% of the class. The filer confirms it owns 5 percent or less of the company’s common stock.
Lincoln Alternative reports no sole or shared voting or dispositive power over any GRO Bio shares and certifies the securities are not held to change or influence control of the issuer. The filing formally updates regulatory records to reflect the firm’s lack of beneficial ownership.
GRI Bio, Inc. filed a current report describing that it issued a press release on February 4, 2026. The release reiterates the company’s financial results for fiscal year 2025 and summarizes key recent business highlights.
The press release is furnished as Exhibit 99.1 and is not incorporated by reference into other SEC filings or deemed filed for liability purposes.
GRI Bio, Inc. is a clinical‑stage biopharmaceutical company developing immune‑modulating therapies for inflammatory, fibrotic and autoimmune diseases, led by oral iNKT‑cell inhibitor GRI‑0621 for idiopathic pulmonary fibrosis (IPF) and dNKT‑cell agonist GRI‑0803 for lupus.
A 35‑patient Phase 2a IPF trial of GRI‑0621 met its primary safety endpoint and evaluated multiple biomarker and lung‑function measures, with no treatment‑related serious adverse events and generally manageable side effects. The company plans, subject to FDA input and additional funding, a Phase 2b study that could support conditional EU approval and potential U.S. registration.
GRI‑0803 showed disease‑modifying signals in preclinical lupus nephritis models, and the company aims to file an IND and start Phase 1a/1b studies in 2026. GRI emphasizes broad NKT‑cell biology expertise and a patent estate with expected expiries around 2032–2035.
The business remains highly dependent on raising substantial additional capital, and management has expressed substantial doubt about the company’s ability to continue as a going concern. The filing also highlights Nasdaq listing risk and previously identified material weaknesses in internal controls, only partially remediated.
GRI Bio, Inc. amended its at-the-market stock offering program with H.C. Wainwright & Co., increasing the potential aggregate offering price from $10,000,000 to up to an aggregate of $60,000,000 of common shares under its existing prospectus supplement.
The amendment, effective as of January 28, 2026, is supported by a new prospectus supplement filed on January 29, 2026 and related legal opinion from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Certain provisions of a December 11, 2025 Securities Purchase Agreement were waived to permit issuances under the updated at-the-market arrangement.
GRI Bio, Inc. is updating its at-the-market stock offering to permit sales of up to $60,000,000 of common stock through H.C. Wainwright & Co. as sales agent.
The company has already sold shares for an aggregate purchase price of $12,639,002.84 under the existing program. As of January 29, 2026, its public float was approximately $86.6 million, based on 1,445,015 shares of common stock held by non-affiliates. The stock last traded at $4.11 per share on the Nasdaq Capital Market on January 28, 2026.